ATTICUS Amendment B – Apixaban for treatment of embolic stroke of undetermined source

ATTICUS Amendment C – Apixaban for treatment of embolic stroke of undetermined source

Axiomatic - BMS – A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)